Induction chemotherapy meta-analysis in head and neck cancer: Right answer, wrong question

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages 2844-2846

  Forastiere, Arlene A ^a   Adelstein, David J ^b   Manola, Judi ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; EDITORIAL; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 84889778524     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.3136     Document Type: Editorial

References (19)

1. Argiris A, Karamouzis MV, Raben D, et al: Head and neck cancer. Lancet 371:1695-1709, 2008
2. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data - MACH-NC Collaborative Group: Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
3. Pignon JP, le Maître A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
4. Hitt R, López-Pousa A, Martínez-Trufero J, et al: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636-8645, 2005
5. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007
6. Pointreau Y, Garaud P, Chapet S, et al: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498-506, 2009
7. Lorch JH, Goloubeva O, Haddad RI, et al: Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153-159, 2011
8. Hitt R, Grau JJ, Lopez-Pousa A, et al: Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 27:303s, 2009 (suppl; abstr 6009)
9. Cohen EEW, Karrison T, Kocherginsky M, et al: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30:356s, 2012 (suppl; abstr 5500)
10. Haddad R, O'Neill A, Rabinowits G, et al: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol 14:257-264, 2013
11. Blanchard P, Bourhis J, Lacas B, et al: Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: An individual patient data meta-analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer group. J Clin Oncol 31:2854-2860, 2013
12. Blettner M, Sauerbrei W, Schlehofer B, et al: Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28:1-9, 1999
13. Baujat B, Audry H, Bourhis J, et al: Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64:47-56, 2006
14. Blanchard P, Hill C, Guihenneuc-Jouyaux C, et al: Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol 64:985-992, 2011
15. Blanchard P, Baujat B, Holostenco V, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol 100:33-40, 2011
16. Pignon JP, Hill C: Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2:475-482, 2001
17. Moher D, Cook DJ, Eastwood S, et al: Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement - Quality of Reporting of Meta-analyses. Lancet 354:1896-1900, 1999
18. Moher D, Pham B, Jones A, et al: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352:609-613, 1998
19. Higgins JP, Altman DG, Gøtzsche PC, et al: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928, 2011